A citation-based method for searching scientific literature

Nicola Flaum, Emma J Crosbie, Richard J Edmondson, Miriam J Smith, Dafydd G Evans. Clin Genet 2020
Times Cited: 8







List of co-cited articles
56 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
575
50

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
879
50

Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
335
37

Ovarian cancer: epidemiology and risk factors.
Carlo La Vecchia. Eur J Cancer Prev 2017
103
37

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
484
37

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
564
37

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Asima Mukhopadhyay, Elizabeth R Plummer, Ahmed Elattar, San Soohoo, Bisha Uzir, Jennifer E Quinn, W Glenn McCluggage, Perry Maxwell, Harriet Aneke, Nicola J Curtin,[...]. Cancer Res 2012
66
37

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
717
37

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
37

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
37

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, Lior Z Braunstein, Rosa Karlic, Nicholas J Haradhavala, Grace Tiao, Daniel Rosebrock, Dimitri Livitz, Kirsten Kübler, Kent W Mouw,[...]. Nat Genet 2017
206
37

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
665
37

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
538
37

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
968
37

Improved survival in women with BRCA-associated ovarian carcinoma.
Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
338
25

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
201
25

Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy.
Chuchu Zhao, Saisai Li, Menghuang Zhao, Haiyan Zhu, Xueqiong Zhu. Arch Gynecol Obstet 2018
15
25

Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants.
Kandamurugu Manickam, Adam H Buchanan, Marci L B Schwartz, Miranda L G Hallquist, Janet L Williams, Alanna Kulchak Rahm, Heather Rocha, Juliann M Savatt, Alyson E Evans, Loren M Butry,[...]. JAMA Netw Open 2018
75
25

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
Honglin Song, Mine S Cicek, Ed Dicks, Patricia Harrington, Susan J Ramus, Julie M Cunningham, Brooke L Fridley, Jonathan P Tyrer, Jennifer Alsop, Mercedes Jimenez-Linan,[...]. Hum Mol Genet 2014
74
25

Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Bing Xia, Qing Sheng, Koji Nakanishi, Akihiro Ohashi, Jianmin Wu, Nicole Christ, Xinggang Liu, Maria Jasin, Fergus J Couch, David M Livingston. Mol Cell 2006
531
25

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
316
25

BRCA population screening for predicting breast cancer: for or against?
Giuseppe Lippi, Camilla Mattiuzzi, Martina Montagnana. Ann Transl Med 2017
10
25

Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R Frankum, Georgina Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie Snape,[...]. Nat Genet 2011
309
25

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Valérie Bonadona, Bernard Bonaïti, Sylviane Olschwang, Sophie Grandjouan, Laetitia Huiart, Michel Longy, Rosine Guimbaud, Bruno Buecher, Yves-Jean Bignon, Olivier Caron,[...]. JAMA 2011
576
25

TP53 mutations in human cancers: origins, consequences, and clinical use.
Magali Olivier, Monica Hollstein, Pierre Hainaut. Cold Spring Harb Perspect Biol 2010
850
25

Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants.
Sarah Jervis, Honglin Song, Andrew Lee, Ed Dicks, Jonathan Tyrer, Patricia Harrington, Douglas F Easton, Ian J Jacobs, Paul P D Pharoah, Antonis C Antoniou. J Med Genet 2014
33
25

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
M Moschetta, A George, S B Kaye, S Banerjee. Ann Oncol 2016
84
25

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
757
25

A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
Tuya Pal, Jenny Permuth-Wey, Thomas A Sellers. Cancer 2008
61
25

Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
N A J Ryan, D G Evans, K Green, E J Crosbie. Gynecol Oncol 2017
37
25

Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Hsiao-Mei Lu, Shuwei Li, Mary Helen Black, Shela Lee, Robert Hoiness, Sitao Wu, Wenbo Mu, Robert Huether, Jefferey Chen, Srijani Sridhar,[...]. JAMA Oncol 2019
66
25

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
25

High-grade serous ovarian cancer: the clone wars.
Aleksander Salomon-Perzyński, Magdalena Salomon-Perzyńska, Bogdan Michalski, Violetta Skrzypulec-Plinta. Arch Gynecol Obstet 2017
23
25

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers.  2017
421
25

Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.
Henry T Lynch, Murray Joseph Casey, Carrie L Snyder, Chhanda Bewtra, Jane F Lynch, Matthew Butts, Andrew K Godwin. Mol Oncol 2009
120
25

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Yvette Drew, Evan A Mulligan, Wan-Tse Vong, Huw D Thomas, Samra Kahn, Suzanne Kyle, Asima Mukhopadhyay, Gerrit Los, Zdenek Hostomsky, Elizabeth R Plummer,[...]. J Natl Cancer Inst 2011
178
25


Integrated analysis of germline and somatic variants in ovarian cancer.
Krishna L Kanchi, Kimberly J Johnson, Charles Lu, Michael D McLellan, Mark D M Leiserson, Michael C Wendl, Qunyuan Zhang, Daniel C Koboldt, Mingchao Xie, Cyriac Kandoth,[...]. Nat Commun 2014
174
25

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
Xin Yang, Goska Leslie, Alicja Doroszuk, Sandra Schneider, Jamie Allen, Brennan Decker, Alison M Dunning, James Redman, James Scarth, Inga Plaskocinska,[...]. J Clin Oncol 2020
77
25

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
783
25

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Barbara Norquist, Kaitlyn A Wurz, Christopher C Pennil, Rochelle Garcia, Jenny Gross, Wataru Sakai, Beth Y Karlan, Toshiyasu Taniguchi, Elizabeth M Swisher. J Clin Oncol 2011
360
25

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
715
25

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
I Ruscito, D Dimitrova, I Vasconcelos, K Gellhaus, T Schwachula, F Bellati, R Zeillinger, P Benedetti-Panici, I Vergote, S Mahner,[...]. Eur J Cancer 2014
53
25

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
320
25

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
294
25

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Nicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, Aron C Eklund, Yang Li, Joyce Liu, Zoltan Szallasi, Ursula A Matulonis, Andrea L Richardson, J Dirk Iglehart,[...]. PLoS One 2013
95
25

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Wataru Sakai, Elizabeth M Swisher, Beth Y Karlan, Mukesh K Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J Farrugia, Fergus J Couch,[...]. Nature 2008
638
25

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, Alexander Gutin, Larissa A Meyer, Darl D Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn,[...]. J Clin Oncol 2010
240
25

TP53 mutations in epithelial ovarian cancer.
Yu Zhang, Lan Cao, Daniel Nguyen, Hua Lu. Transl Cancer Res 2016
37
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.